Two 12-week phase 3 trials and a 43-week extension will test 8 mg and 16 mg HLP003 added to antidepressants, with APPROACH enrollment now complete.
|Articles|September 16, 2008
- October31 2003
- Volume 10
- Issue 20
Entrepreneurial Living
Advertisement
Entrepreneur
In today's competitive business climate,physicians not only must becompetent healers, but they also haveto be good businesspeople. Whereyou practice also helps. magazine (www.entrepreneur.com)recently released its 10th annual"Best Cities for Entrepreneurs" list.Here are the top 10:
- Minneapolis/St. Paul, Minn
- Washington, DC
- Atlanta, Ga
- Fort Lauderdale, Fla
- Salt Lake City, Utah
- West Palm Beach, Fla
- Norfolk/Virginia Beach, Va
- Miami, Fla
- Charlotte, NC, Gastonia, NC, and Rock Hill, SC
- Orlando, Fla
Note:
Judging criteria include entrepreneurialactivity, small-businessgrowth, job growth, and risk.
Articles in this issue
about 18 years ago
Consider the State of Retirement Todayabout 18 years ago
Bequeathing a Home Can Cause Unrestabout 18 years ago
Don't Wear Your Raincoat in the Showerabout 18 years ago
Portfolio CHECK-UPabout 18 years ago
Red, White, and…Green?about 18 years ago
Who Decides How Much Is Too Much?about 18 years ago
Do You Need Long-term Care Insurance?about 18 years ago
Surplus Malpractice Coverage Has Perksabout 18 years ago
Separate Second Home Fantasy from Factabout 18 years ago
Take Advantage of Savings OpportunitiesAdvertisement
Related to this article
This preview of EADV 2026 provides a teaser of new data and interviews being highlighted at this Vienna dermatology conference.
Phase 2b AMPLIFIED data show a 42.7% UACR drop in AMKD with modest proteinuria; AMPLITUDE interim data are due early 2027.
George Vasquez-Rios, MD, explains how the ASN's GD-C Compendium curates glomerular disease guidance for general clinicians and specialists alike.
Andrew Cutler, MD, says real-world MDD patients respond to adjunctive cariprazine like trial participants, with gains in mood and function within weeks.
Frances Lee, MD, on the stigma driving under-detection of ALD and its disproportionate rise in women and younger adults.
SOCS leaders explain SOCS Serves, a toolkit-based program connecting dermatology volunteers with students and underserved communities.
EMBARQ-CSU1 and EMBARQ-CSU2 showed sustained reductions in urticaria, with the antibody meeting all primary and key secondary endpoints at Week 12.
Advertisement
Advertisement
Trending on HCPLive
1
Half-Life vs. Real Life: How Real-World Evidence Is Reframing Wet AMD Treatment
2
ProACt Data Show Early Functional Gains with Adjunctive Cariprazine In MDD
3
FDA Updates Sotatercept Label with HYPERION Data in Early PAH
4
EMBARQ-CSU: Barzolvolimab Meets Primary, Secondary Endpoints in CSU Trials
5